Why have so many drugs with stellar results in laboratory stroke models failed in clinical trials? A theory based on allometric relationships

Annals of the New York Academy of Sciences

Volumn 993, Issue , 2003, Pages 69-74

  Curry, Stephen H ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b Stephen H Curry Consulting   (United States)

Author keywords

Allometric relationships; Clinical trials; Laboratory stroke models

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; APTIGANEL; CITICOLINE; CLOMETHIAZOLE; EBSELEN; ELIPRODIL; EMLIMOLAB; FLUNARIZINE; FOSPHENYTOIN SODIUM; GANGLIOSIDE GM1; GLUTAMIC ACID; LUBELUZOLE; NEUROPROTECTIVE AGENT; NIMODIPINE; PIRACETAM; TIRILAZAD; UNCLASSIFIED DRUG;

ALLOMETRY; AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; CEREBROSPINAL FLUID LEVEL; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DATA ANALYSIS; DISEASE COURSE; DRUG EFFICACY; HUMAN; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SIDE EFFECT; STROKE; THEORY; TREATMENT FAILURE;

ANIMALIA;

EID: 0037713477     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb07512.x     Document Type: Conference Paper

References (23)

1. DE KEYSER, J., G. SUTTER & G. LUTTEN. 1999. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci. 22: 535-540.
2. MARTINEZ-VILA, E. & P.I. SIEIRA. 2001. Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc. Dis. 11: 60-70.
3. LYDEN, P., A. SHUAIB, K. NG, et al. 2002. Clomethiazole acute stroke study in ischemic stroke (CLASS I) final results. Stroke 33: 22-128.
4. DIENER, H.C., M. CORTENS, G. FORD, et al. 2000. Lubelazole in acute ischaemic stroke treatment. A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubelazole with placebo. Stroke 31: 2543-2551.
5. LEES, K.R., A.G. DYKER, A. SHARMA, et al. 2001. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R 15896 AR in stroke patients. A dose-ranging study. Stroke 32: 466-472.
6. LEES, K.R., A.K. SHARMA, D. BARER, et al. 2001. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 32: 675-680.
7. KURODA, S., P. TSUCHUDATA, M.-L. SMITH, et al. 1999. Neuroprotective effects of a novel nitrone NXY-059 after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 19: 778-787.
8. JONAS, S., V. AIYAGARI, D. VIEIRA & M. FIGUEROA. 2001. The failure of neuronal protective agents versus the success of thrombolysis in the treatment of ischemic strike. Ann. N.Y. Acad. Sci. 939: 257-267.
9. MARSHALL, J.W.B., A.J. CROSS & R.M. RIDLEY. 1999. Functional benefit from clomethiazole treatment after focal cerebral ischemia in a nonhuman primate species. Exp. Neurol. 156: 121-129.
10. WAHLGREN, N.G., E. DIEZ-TEJELOR, J. TEITELBAUM, et al. 2000. Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients. Stroke 31: 82-85.
11. INGS, R.M.J. 1990. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20: 1201-1231.
12. BENEVISTE, H., J. DREJER, A. SCHOUSBOE & N.H. DIEMER. 1984. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43: 1369-1374.
13. BULLOCK, R., A. ZAUNER, J. WOODWARD & H.F. YOUNG. 1995. Massive persistent release of excitatory amino acids following human occlusive stroke. Stroke 26: 2187-2189.
14. ROTHMAN, S.M. & J.W. OLNEY. 1986. Glutamate and the pathophysiology of hypoxicischemic brain damage. Ann. Neurol. 19: 105-111.
15. HILLERED, L., A. HALLSTROM, S. SEGERSVARD, et al. 1989. Dynamics of extracellular metabolites in the striatum after middle cerebral artery occlusion in the rat monitored by intracerebral microdialysis. J. Cereb. Blood Flow Metab. 9: 607-616.
16. CASTILLO, J., A. DAVALOS & M. NOGA. 1997. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 349: 79-83.
17. DAVALOS, A., J. CASTILLO, J. SERENA & M. NOGA. 1997. Duration of glutamate release after acute ischemic stroke. Stroke 28: 708-710.
18. CASTILLO, J., A. DAVALOS, J. NAVEIRO & M. NOGA. 1996. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 27: 1060-1065.
19. PARSONS, C.G., W. DANYSZ & G. QUACK. 1998. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11: 523-569.
20. MARINI, A.M. & S.M. PAUL. 1992. N-Methyl-D-aspartate receptor-mediated neuroprotection in cerebellar granule cells requires new RNA and protein synthesis. Proc. Natl. Acad. Sci. USA 89: 6555-6559.
21. JIANG, X., D. ZHU, P. OKAGAKI, R.H. LIPSKY, et al. 2003. N-Methyl-D-aspartate and TrkB receptor activation in cerebellar granule cells. Ann. N.Y. Acad. Sci. 993: this volume.
22. MARSHALL, J.W.B., E.J. JONES, K.J. DUFFIN, et al. 2000. AR-R 15896 AR, a low-affinity, use-dependent, NMDA antagonist, is neuroprotective in a primate model of stroke. J. Stroke Cerebrovasc. Dis. 9: 303-312.
23. CURRY, S.H. 2001. On the relationship between plasma concentrations of drugs and outcome of stroke studies in laboratory animals. Ann. N.Y. Acad. Sci. 939: 297-308.